Dual HER2 blockade with pertuzumab (P) and trastuzumab (T) in patients with HER2-positive metastatic breast cancer (mBC) relapsing after adjuvant treatment with T: results from a German non-interventional study (NIS) HELENA (NCT01777958)

NIS HELENA documented outcomes in clinical routine practice of first-line therapy with P plus T and docetaxel (D) of patients with advanced HER2-positive BC and prior (neo)adjuvant T.

Saved in:

Bibliographic Details
Main Authors:	Thill, Marc (Author) , Wimberger, Pauline (Author) , Grafe, Andrea (Author) , Klare, Peter (Author) , Luedtke-Heckenkamp, Kerstin (Author) , Reichert, Dietmar (Author) , Zaiss, Matthias (Author) , Ziegler-Löhr, Katja (Author) , Eckl, Tanja (Author) , Schneeweiss, Andreas (Author)
Format:	Article (Journal)
Language:	English
Published:	12 September 2022
In:	Breast cancer research and treatment Year: 2022, Volume: 196, Issue: 2, Pages: 311-321
ISSN:	1573-7217
DOI:	10.1007/s10549-022-06710-4
Online Access:	Verlag, kostenfrei, Volltext: https://doi.org/10.1007/s10549-022-06710-4 Verlag, kostenfrei, Volltext: https://link.springer.com/article/10.1007/s10549-022-06710-4
Author Notes:	Marc Thill, Pauline Wimberger, Andrea Grafe, Peter Klare, Kerstin Luedtke-Heckenkamp, Dietmar Reichert, Matthias Zaiss, Katja Ziegler-Löhr, Tanja Eckl, Andreas Schneeweiss

Description
Summary:	NIS HELENA documented outcomes in clinical routine practice of first-line therapy with P plus T and docetaxel (D) of patients with advanced HER2-positive BC and prior (neo)adjuvant T.
Item Description:	Gesehen am 27.06.2023
Physical Description:	Online Resource
ISSN:	1573-7217
DOI:	10.1007/s10549-022-06710-4